Survey on Occurrence of Hepatitis: A Case Study


  • Shivam Shekhar Amity Institute of Pharmacy Lucknow, Amity University Uttar Pradesh, India



Reactivation of HBV, DAA treatment, HCV infection


Background: The hepatitis B virus (HBV) may reactivate. The patients who were found in accordance with Egyptian guidelines from February 2019 to December 2019. On the other hand, it was seen that those patients had just contracted HBV. Results: Of all participants, 51% of them were women and 49% of them were men above the age of 18. The results of four weeks, and the conclusion of the 12-week treatment period all showed improvement, with the exception of serum albumin, and this difference was highly statistically significant. 34 individuals with Co-infections with and results l were present at the start of the investigation. Reactivation was found in 6 individuals after 1 month of DAA treatment. Conclusion: In order to identify new infection or the reactivation of a preexisting infection during or after DAA medication, screening for HBV infection is necessary.


Download data is not yet available.


Kao J-H. Hepatitis C virus infection in Taiwan: Past, present, and future. J Formos Med Assoc [Internet]. 2016;115(2):65–6. Available from:

Abo-Amer YE-E, Abd-Elsalam S, Eldosoky H, ELShenawy AK, Awny S, Elagawy W, et al. Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt. Infect Drug Resist [Internet]. 2018;11:2435–41. Available from:

Abd-Elsalam S, Badawi R, Elnawasany S, Yousef M, Mansour L, Hawash N, et al. Sofosbuvir, pegylated interferon and ribavirin in treatment of an Egyptian cohort with hepatitis C virus infection in real life clinical practice. Infect Disord Drug Targets [Internet]. 2018;18. Available from:

Liu C-H, Liu C-J, Su T-H, Fang Y-J, Yang H-C, Chen P-J, et al. Hepatitis B virus reactivation in patients receiving interfer-on-free direct-acting antiviral agents for chronic hepatitis C virus infection. Open Forum Infect Dis [Internet]. 2017;4(1). Available from:

Programmes STI. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021 [Internet]. World Health Organization; 2021 [cited 2023 Feb 26]. Available from:

Soliman H, Ziada D, Salama M, Hamisa M, Badawi R, Hawash N, et al. Predictors for fibrosis regression in chronic HCV patients after the treatment with DAAS: Results of a real-world cohort study. Endocr Metab Immune Disord Drug Targets [Internet]. 2020;20(1):104–11. Available from:

Hanafy AS, Soliman S, Abd-Elsalam S. Rescue therapy for chronic hepatitis C virus infection after repeated treatment failures: Impact on disease progression and risk of hepatocellular carcinoma. Hepatol Res [Internet]. 2019;49(4):377–84. Available from:

EASL recommendations on treatment of hepatitis C 2016. J Hepatol [Internet]. 2017;66(1):153–94. Available from:

Bircher J, Benhamou N, Mcintyre M, Rizzetto J. hepatology textbook published by Oxford. Oxford University Press; 1999.

Sherlock S, Dooley J, editors. Diseases of the liver and biliary system [Internet]. Wiley; 2001. Available from:

Schiff ER, Sorrels MF, Ec M. Liver diseases according to Schiff. Williams & Wilkins; 2003.

Popper H and Schaffner H. The sinusoids' capillarization. Gastroenterology.

Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol [Internet]. 2004;40(5):860–7. Available from:

Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Arch Pathol Lab Med [Internet]. 2000;124(11):1599–607. Available from:

Digestive illnesses in the US: Epidemiology and Impact, Arch Pathol Lab Med Bethesda, MD: 1994; NIDDK.

Johnson SE, Sherding RG. Diseases of the liver and biliary tract. In: Saunders Manual of Small Animal Practice. Else-vier; 2006. p. 747–809.

PCC 006




How to Cite

Shekhar S. Survey on Occurrence of Hepatitis: A Case Study. Int. J. Primary Crit. Care [Internet]. 2023 Sep. 30 [cited 2024 Jul. 25];1(1):1-6. Available from:




Case Study